MicroRNAs in Huntington's disease: diagnostic biomarkers or therapeutic agents?
X Dong, S Cong - Frontiers in cellular neuroscience, 2021 - frontiersin.org
MicroRNA (miRNA) is a non-coding single-stranded small molecule of approximately 21
nucleotides. It degrades or inhibits the translation of RNA by targeting the 3′-UTR. The …
nucleotides. It degrades or inhibits the translation of RNA by targeting the 3′-UTR. The …
Pharmacogenetics in the treatment of Huntington's disease: review and future perspectives
X García-González, E Cubo, L Simón-Vicente… - Journal of Personalized …, 2023 - mdpi.com
Huntington's disease (HD) is an autosomal dominant progressive brain disorder, caused by
a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic …
a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic …
A novel Huntington's disease assessment platform to support future drug discovery and development
J Wu, L Möhle, T Brüning, I Eiriz, M Rafehi… - International Journal of …, 2022 - mdpi.com
Huntington's disease (HD) is a lethal neurodegenerative disorder without efficient
therapeutic options. The inefficient translation from preclinical and clinical research into …
therapeutic options. The inefficient translation from preclinical and clinical research into …
[HTML][HTML] Why Woody got the blues: The neurobiology of depression in Huntington's disease
Huntington's disease (HD) is an extraordinary disorder that usually strikes when individuals
are in the prime of their lives, as was the case for the influential 20th century musician …
are in the prime of their lives, as was the case for the influential 20th century musician …
Recent developments in the management of Huntington's disease
SJ Devadiga, SS Bharate - Bioorganic Chemistry, 2022 - Elsevier
Huntington's disease (HD) is a rare, incurable, inherited neurodegenerative disorder
manifested by chorea, hyperkinetic, and hypokinetic movements. The FDA has approved …
manifested by chorea, hyperkinetic, and hypokinetic movements. The FDA has approved …
A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease
MR Islam, MH Jony, GK Thufa, S Akash, PS Dhar… - Molecular …, 2024 - Springer
A neurodegenerative disorder (ND) refers to Huntington's disease (HD) which affects
memory loss, weight loss, and movement dysfunctions such as chorea and dystonia. In the …
memory loss, weight loss, and movement dysfunctions such as chorea and dystonia. In the …
Treatment of depression in Huntington's disease: a systematic review
SA Zadegan, F Ramirez, KS Reddy… - The Journal of …, 2024 - Am Neuropsych Assoc
Depression is a common psychiatric disorder among individuals with Huntington's disease
(HD). Depression in HD and major depressive disorder appear to have different …
(HD). Depression in HD and major depressive disorder appear to have different …
[HTML][HTML] Environmental stimulation in Huntington disease patients and animal models
While Huntington disease (HD) is caused solely by a polyglutamine expansion in the
huntingtin gene, environmental factors can influence HD onset and progression. Here, we …
huntingtin gene, environmental factors can influence HD onset and progression. Here, we …
The comprehensive analysis of motor and neuropsychiatric symptoms in patients with Huntington's disease from China: a cross-sectional study
Y Cheng, X Gu, K Liu, T Yang, Y **ao, Q Jiang… - Journal of clinical …, 2022 - mdpi.com
Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder
caused by CAG repeats expansion. There is a paucity of comprehensive clinical analysis in …
caused by CAG repeats expansion. There is a paucity of comprehensive clinical analysis in …
Genetic risk for Huntington Disease and reproductive decision‐making: A systematic review
Huntington Disease (HD) is an incurable autosomal dominant single gene
neurodegenerative disorder. Typical onset is between 30 and 40 years and characterised by …
neurodegenerative disorder. Typical onset is between 30 and 40 years and characterised by …